Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2014, Article ID 162534, 4 pages
http://dx.doi.org/10.1155/2014/162534
Case Report

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma

1Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
2Department of Oncology, Tata Medical Centre, Kolkata 700 156, India
3Department of Otolaryngology, Sunderland Royal Hospital, Kayll Road, Sunderland SR4 7TP, UK

Received 1 June 2014; Accepted 10 July 2014; Published 17 July 2014

Academic Editor: Jose I. Mayordomo

Copyright © 2014 Muhammad Shahid Iqbal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. W. House and D. E. Brackmann, “Facial nerve grading system,” Otolaryngology-Head and Neck Surgery, vol. 93, no. 2, pp. 146–147, 1985. View at Google Scholar · View at Scopus
  2. F. L. Greene, D. L. Page, I. D. Fleming et al., Eds., AJCC Cancer Staging Manual, Springer, New York, NY, USA, 6th edition, 2002.
  3. P. M. Speight and A. W. Barrett, “Salivary gland tumours,” Oral Diseases, vol. 8, no. 5, pp. 229–240, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. W. J. Kane, T. V. McCaffrey, K. D. Olsen, and J. E. Lewis, “Primary parotid malignancies. a clinical and pathologic review,” Archives of Otolaryngology: Head and Neck Surgery, vol. 117, no. 3, pp. 307–315, 1991. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Hosal, C. Fan, L. Barnes, and E. N. Myers, “Salivary duct carcinoma,” Otolaryngology—Head and Neck Surgery, vol. 129, no. 6, pp. 720–725, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. B. McHugh, D. W. Visscher, and E. L. Barnes, “Update on selected salivary gland neoplasms,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 11, pp. 1763–1774, 2009. View at Google Scholar · View at Scopus
  7. L. M. Vargas-Roig, F. E. Gago, O. Tello et al., “c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy,” International Journal of Cancer, vol. 84, pp. 129–134, 1999. View at Google Scholar
  8. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. J. Bang, E. van Cutsem, and A. Feyereislova, “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer ( ToGA ): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar
  10. M. Agulnik and L. L. Siu, “An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents,” Current Medicinal Chemistry—Anti-Cancer Agents, vol. 4, no. 6, pp. 543–551, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Nardi, P. M. Sadow, D. Juric et al., “Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment,” Clinical Cancer Research, vol. 19, no. 2, pp. 480–490, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Etges, D. S. Pinto Jr., L. P. Kowalski, F. A. Soares, and V. C. Araújo, “Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour,” Journal of Clinical Pathology, vol. 56, no. 12, pp. 914–918, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Haddad, A. D. Colevas, J. F. Krane et al., “Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study,” Oral Oncology, vol. 39, no. 7, pp. 724–727, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Agulnik, E. W. E. Cohen, R. B. Cohen et al., “Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3978–3984, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. U. Lin and E. P. Winer, “Brain metastases: the HER2 paradigm,” Clinical Cancer Research, vol. 13, no. 6, pp. 1648–1655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Bartolotti, E. Franceschi, and A. A. Brandes, “Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts,” Future Oncology, vol. 9, no. 11, pp. 1653–1664, 2013. View at Google Scholar
  17. S. A. Limaye, M. R. Posner, J. F. Krane et al., “Trastuzumab for the treatment of salivary duct carcinoma,” Oncologist, vol. 18, no. 3, pp. 294–300, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Kadowaki, Y. Yatabe, H. Hirakawa et al., “Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma,” Case Reports in Oncology, vol. 6, no. 3, pp. 450–455, 2013. View at Publisher · View at Google Scholar
  19. B. Firwana, B. Atassi, R. Hasan, N. Hasan, and A. Sukari, “Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: case report and review of the literature,” Avicenna Journal of Medicine, vol. 2, no. 3, pp. 71–73, 2012. View at Google Scholar
  20. M. Nashed and R. J. Casasola, “Biological therapy of salivary duct carcinoma,” Journal of Laryngology and Otology, vol. 123, no. 2, pp. 250–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Prat, M. Parera, V. Reyes et al., “Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy,” Head & Neck, vol. 30, no. 5, pp. 680–683, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Sharon, R. J. Kelly, and E. Szabo, “Sustained response of carcinoma expleomorphic adenoma treated with trastuzumab and capecitabine,” Head and Neck Oncology, vol. 2, no. 1, article 12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Kaidar-Person, S. Billan, and A. Kuten, “Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review,” Medical Oncology, vol. 29, no. 2, pp. 704–706, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. L. D. Locati, G. Rinaldi, P. Bossi et al., “Herceptin® plus chemotherapy in relapsed and/or metastatic salivary gland cancer [1],” Oral Oncology, vol. 41, no. 1, pp. 97–98, 2005. View at Publisher · View at Google Scholar · View at Scopus